TABLE 1.
mAbs |
MW (kDa) | FcRn binding in rabbit | Target binding in rabbit | Solute radius (nm) | KD-FcRn (µmol/L) | RCL (mL/min/kg) |
---|---|---|---|---|---|---|
Anti-gD IgG | 150 | Yes | No | 4.13 | 2.52 | ‐ |
Anti-gD null IgG | 150 | Yes | No | 4.13 | 13.3 | ‐ |
Anti-gD Fab | 50 | No | No | 3.30 | ‐ | 0.70 |
Anti-gD F(ab)2 | 100 | No | No | 3.07 | ‐ | 0.05 |
Anti-gD Fc | 50 | Yes | No | 2.40 | 1.30 | 0.04 |
Anti-VEGF Fab | 50 | No | Yes | 2.40 | ‐ | 0.56 |
Anti-VEGF F(ab)2 | 100 | No | Yes | 3.70 | ‐ | 0.10 |
Obiltoxaximab (IgG) | 148 | Yes | No | 4.13 | 7.95 | ‐ |
rabIgG (IgG) | 150 | Yes | No | 4.86 | 3.40 | ‐ |
Conbercept (Fc fusion) | 143 | Yes | Yes | 3.00 | 2.59 | ‐ |